Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6–10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblastoma. Patients received up to four cycles of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Emil, Peters, Katherine B, Sumrall, Ashley L, Desjardins, Annick, Reardon, David A, Lipp, Eric S, Herndon, James E, Coan, April, Bailey, Leighann, Turner, Scott, Friedman, Henry S, Vredenburgh, James J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639657/
https://www.ncbi.nlm.nih.gov/pubmed/23634286
http://dx.doi.org/10.1002/cam4.58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639657/
https://www.ncbi.nlm.nih.gov/pubmed/23634286
http://dx.doi.org/10.1002/cam4.58

Ejemplares similares